Pediatric exclusivity: evolving legislation and novel complexities within pediatric therapeutic development.

Area of Science:

• Pharmacology and Therapeutics
• Pediatric Drug Development
• Regulatory Science

Background:

• Pediatric drug development is underfunded, leading to a lack of appropriately labeled medications for children.
• Legislation like the Food and Drug Administration Modernization Act (FDAMA) and Food and Drug Administration Amendments Act (FDAAA) introduced market exclusivity incentives to address this deficit.
• The program grants a 6-month patent extension for initiating pediatric clinical investigations, aiming to improve pediatric indications and dosing knowledge.

Purpose of the Study:

• To review the successes and omissions of the Food and Drug Administration (FDA) pediatric exclusivity incentive program.
• To evaluate the effectiveness of current legislation in fostering meaningful pediatric drug development.

Main Methods:

• Examined drugs granted exclusivity using the FDA's published database.
• Reviewed relevant drug labeling and postmarket safety studies.
• Assessed whether studies supporting patent protection adequately addressed current pediatric needs.

Main Results:

• Studies conducted to gain exclusivity are frequently not designed to meet current pediatric needs.
• The incentive program has not consistently resulted in improved pediatric drug labeling or dosing information.

Conclusions:

• Amendments to the Food and Drug Administration Amendments Act (FDAAA) are necessary.
• Future studies for exclusivity should focus on relevant pediatric indications, significant disease burdens, and appropriate age ranges.
• Exclusivity should not be granted for studies with identified safety concerns prior to initiation.
• Incentives could be enhanced for trials yielding significant contributions to pediatric dosing knowledge or labeling changes.